Novo Nordisk (NVO) and Viking Therapeutics (VKTX) have emerged as notable players in the obesity space.A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs under brand names Ozempic (pre-filled pen) and Rybelsus (oral tablet) for type II diabetes (T2D), and Wegovy (injection) for chronic weight management.On the other hand, Viking Therapeutics is a clinical-stage biotech firm. Its investigational dual GIP and GLP-1 receptor agonist, VK2735, has shown blockbuster potential in early ...

Core Viewpoint - Pepsi was once regarded as a top consumer staple due to its consistent dividend growth over 50 years and strong share performance, but recent developments may indicate a shift in its market position [1] Financial Performance - Pepsi has maintained a growing dividend for 50 consecutive years, highlighting its commitment to returning value to shareholders [1] - The company's share price performance has been strong historically, contributing to its reputation as a reliable investment [1] Market Position - The perception of Pepsi as a leading consumer staple has changed over the past two years, suggesting potential challenges in its market standing [1]

The Zacks Oil and Gas - Refining & Marketing MLP industry faces notable headwinds. Inflation and economic slowdowns are weighing on fuel demand and compressing margins. Lower commodity prices and uncertainty around tariffs, especially on steel, could further strain midstream earnings. Analyst sentiment reflects this, with industry earnings estimates for 2025 and 2026 trending lower. Still, not all is bleak. Despite a lowly industry rank, some names are bucking the trend. Midstream firms with fee-based model ...

Energy stocks are beginning to reassert their strength as macro conditions improve and demand drivers multiply. With recession fears easing as tariff negotiations show signs of progress, the market backdrop is turning more favorable, and energy names are catching a bid.Adding to the bullish case is the continued global buildout of data centers, which is expected to drive a massive increase in electricity demand. AI infrastructure, cloud computing, and high-performance servers all require significant power, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-32593 Global Partners LP (Exact name of registrant as specified in its charter) Delaware 74-3140887 (State or ot ...

Global Partners (GLP) Q1 2025 Earnings Call May 08, 2025 10:00 AM ET Company Participants Sean T. Geary - Chief Legal OfficerEric Slifka - President, CEO & DirectorGregory Hanson - Chief Financial OfficerSelman Akyol - Managing Director - Energy & Power sectorMark Romaine - COO Operator Good day, everyone, and welcome to the Global Partners First Quarter twenty twenty five Financial Results Conference Call. Today's call is being recorded. All lines have been placed in listen only mode. With us from Global P ...

Global Partners (GLP) Q1 2025 Earnings Call May 08, 2025 10:00 AM ET Speaker0 Good day, everyone, and welcome to the Global Partners First Quarter twenty twenty five Financial Results Conference Call. Today's call is being recorded. All lines have been placed in listen only mode. With us from Global Partners are President and Chief Executive Officer, Mr. Eric Slifka Chief Financial Officer, Mr. Gregory Hansen Chief Operating Officer, Mr. Marc Romaine and Chief Legal Officer and Secretary, Mr. Sean Geary. At ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Gregory B. Hanson Sean T. Geary Global Partners LP Global Partners LP (781) 894-8800 (781) 894-8800 Chief Financial Officer Chief Legal Officer and Secretary Global Partners LP Reports First-Quarter 2025 Financial Results Waltham, Mass., May 8, 2025 – Global Partners LP (NYSE: GLP) today reported financial results for the first quarter ended March 31, 2025. CEO Commentary "Global delivered solid first-quarter results, highlighting the strength of our integrated a ...

More information about the AAPS workshop can be found at https://www.aaps.org/aaps/education-and- research/workshops/diabetes-drug-development. ALAMEDA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the "Company" or "Vivani"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the American Association of Pharmaceutical Scientist ...

Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fat depots, which are strongly linked to increased risk of cardiovascular and metabolic diseases, resulting in a 26% reduction in fat mass with no loss in muscleStrong synergistic effect on fat mass (77% reduction) was observed when the Activin E antibody was combined with a GLP-1 receptor agonist, resulting in total weight loss of 35.3%, 7.5% greater than GLP-1 alone SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- iB ...